BACKGROUND: Late-onset @entity1398 (LON) is a known adverse effect to rituximab therapy. Information about its real incidence and clinical implications comes from case reports and few retrospective studies specifically designed to study LON. However, large prospective studies of LON are lacking in the literature. We aimed to determine the incidence of LON in a group of @entity1893 @entity1 treated with rituximab and to analyze the clinical course, complications, and risk factors associated with LON. @entity1 AND METHODS: We retrospectively reviewed 183 @entity1 with a diagnosis of @entity1893 consecutively treated with rituximab alone or in combination with chemotherapy. RESULTS: We identified 11 @entity1 with grade 3/4 LON (13 episodes) out of 183 @entity1 (6%). The median time to onset of LON was 75 days, and the median time to recovery from @entity1398 was 100 days. The median neutrophil count nadir was 0.55  * 10(9)/L (range, 0.06-0.9  * 10(9)/L). Two @entity1 presented @entity166 , one with fatal outcome. CONCLUSION: In our experience, the incidence of recognized LON is low (6%), although its real incidence may be greater because of the asymptomatic course and quick recovery in most cases. Infectious complications are unusual, but life-threatening complications can emerge. A careful evaluation of all cases of LON is warranted.

Late-Onset @entity1398 After Rituximab-Containing Therapy for XXXX .

@entity1893 :: ('MESH:D008228', 'Disease') :: ['non-Hodgkin lymphoma'] @entity1 :: ('9606', 'Species') :: ['patients', 'PATIENTS'] @entity1398 :: ('MESH:D009503', 'Disease') :: ['neutropenia'] @entity166 :: ('MESH:D003141', 'Disease') :: ['infectious complications']
@entity1893 :: (MESH:D008228,Disease) :: ['Non-Hodgkin Lymphoma']
